AHAnna Henriksson

Anna Henriksson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Henriksson has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does a digital support intervention reduce sedentary behaviour during cancer treatment in individuals with breast, prostate or colorectal cancer? Study protocol for a Swedish multicentre randomised controlled trial

    by Lisa Rådman, Johanna Zetterlund, Petra von Heideken Wågert, Anna Henriksson

    Introduction Sedentary behaviour increases during cancer treatment, often because of side effects from treatment. However, evidence on interventions specifically targeting sedentary behaviour during active cancer treatment is limited. Therefore, the aims of the reduce sedentary behaviour during cancer treatment (RedSedCan) study are to investigate the effects of sedentary behaviour on health outcomes and to explore the economic, environmental and social sustainability perspectives of a digital support intervention for reducing sedentary behaviour in individuals with breast, prostate or colorectal cancer receiving neoadjuvant or adjuvant cancer treatment. In addition, participants’ experiences with the intervention as well as healthcare professionals’ perspectives for supporting individuals with cancer to reduce sedentary behaviour will be explored. Methods and analysis A multicentre randomised controlled trial will be conducted with short-term (3 months) and long-term (6, 12 and 24 months) follow-up. After baseline assessments, participants will be randomised into one of two groups as follows: a digital support intervention group or a control group receiving usual care. The digital support intervention—the RedSedCan intervention—consists of access to a home page containing information and tips about how to reduce sedentary behaviour, a commercially available step-counting mobile application, use of mobile phone reminder/alarm functions and four digital meetings with physiotherapists. During these meetings, participants will receive support for setting and reviewing goals. The main outcome is time spent engaging in sedentary behaviour, which is measured with a thigh-worn accelerometer at 3 months. Secondary outcomes include long-term follow-ups, physical activity, health-related outcomes, health economic effects and greenhouse gas emissions from interventions and healthcare. In addition, the experiences of participants undergoing the intervention and the attitudes and perceived barriers and facilitating factors of healthcare professionals for supporting individuals with cancer to reduce sedentary behaviour will be explored qualitatively. Ethics and dissemination Ethical approval has been obtained from the appropriate ethics review authority. Findings will be disseminated through peer-reviewed publications, conference presentations and other relevant scientific and patient communities. Trial registration number NCT06719206.

  • Open Access

    What is the adherence to an exercise intervention during (neo-)adjuvant chemotherapy among Swedish patients with breast cancer? Data from the Phys-Can randomised controlled trial

    by Anna Henriksson, Andreas Stenling, Anne-Sophie Mazzoni, Katarina Sjövall, Sussanne Börjeson, Sveinung Berntsen, Christopher G Bean, Laurien M Buffart, Karin Nordin, Ingrid Demmelmaier

    Objectives: While exercise adherence is known to vary during cancer treatment, little is known about what predicts these changes during chemotherapy or within individual treatment cycles for breast cancer. We examined changes in adherence and its predictors (1) across chemotherapy treatment and (2) within treatment cycles in women undergoing (neo-)adjuvant chemotherapy for breast cancer. Design: This study is based on data from the Phys-Can multicentre parallel randomised trial. Setting: The exercise intervention was conducted at public gyms in three Swedish university cities. Participants: 178 women undergoing (neo-)adjuvant chemotherapy without any chemotherapy treatment delays and had any adherence data were included in the analysis. Interventions: Participants in the Phys-Can trial were randomised to either high or low-to-moderate intensity combined endurance and resistance training. Primary outcome: The primary outcome variable for this secondary analysis of Phys-Can trial data was adherence to endurance and resistance training. Bayesian multilevel growth curve models were used to examine adherence to resistance and endurance training throughout the chemotherapy treatment period and within chemotherapy cycles. Potential predictors of adherence included exercise intensity, chemotherapy dose, muscle strength, body mass index, cardiorespiratory fitness, fatigue and age. Results are reported with 95% credibility intervals (CrIs). Results: Adherence to endurance and resistance training declined on average across the chemotherapy treatment by 1% (95% CrI −1.5, −0.5) and 5.2% (95% CrI −6.8, −3.6), respectively, per week. Adherence decreased within the chemotherapy treatment cycle by 2.4% for endurance (95% CrI −4.2, −0.7) and 6.1% (95% CrI −8.2, −4.1) for resistance training, respectively. Higher baseline fitness predicted better adherence to endurance exercise ( β =1.2, 95% CrI 0.1, 2.3), while high-intensity training predicted a steeper decline ( β =−1.2, 95% CrI −2.2, 0.2). No significant predictors were found for adherence to resistance training over time. Conclusions: Women with breast cancer may require additional support to maintain exercise adherence during the later stages of chemotherapy and during the second and third weeks of their chemotherapy cycles. Those with lower pretreatment fitness levels may benefit from more intensive support to sustain engagement in exercise. The Phys-Can trial was registered in Clinical trials: ClinicalTrials.gov NCT02473003 ,

  • Open Access

    The Development of a Web-Based Application to Support Informal Caregivers of Individuals With Head and Neck Cancer: Human-Centered Design Approach

    by Awais Ahmad, Åsa Cajander, Ulrica Langegård, Birgitta Johansson, Anna Henriksson, Mona Pettersson, Waqas Ahmad, Ylva Tiblom Ehrsson

    Background: Informal caregivers (ICs), often family members or close friends, provide essential support to individuals with head and neck cancer. However, they are frequently unprepared for the emotional, practical, and medical challenges involved. Web-based applications offer promising opportunities to support ICs, but their long-term adoption and acceptance remain uncertain. Objective: This paper presents the development of Carer eSupport, a web-based application to support ICs’ well-being and preparedness for caregiving. We detail the design and functionality of the Carer eSupport application and explain how it responds to both the functional and psychological needs of ICs. Additionally, we report findings from the pilot study and highlight the initial challenges ICs faced when engaging with the application, along with the strategies used to overcome them. Methods: The study involved a multicenter research trial across ear, nose, and throat clinics and oncology and radiotherapy clinics at 4 university hospitals in Sweden. The application was developed through 3 human-centered design (HCD) iterations involving ICs, health care professionals, and researchers in human-computer interaction and cancer care. Results: The results present an overview of the current version of Carer eSupport (developed during the third design iteration), with a focus on features that address the psychological needs of ICs, including competence, autonomy, and a sense of connection to others. The pilot study achieved a 66.7% (20/30) consent rate, a 75% (9/12) successful login rate among participants, and a 13.3% (4/30) attrition rate, meeting the established criteria. The pilot study confirmed the application’s readiness for further evaluation in an ongoing randomized controlled trial. It also identified challenges, including the time constraints of ICs, login and authentication issues, limited IT infrastructure, and gaps in digital literacy. Conclusions: Findings from the HCD process and pilot study indicate that a personalized, interactive application like Carer eSupport can provide meaningful support for ICs of individuals with head and neck cancer. The integration of HCD and health care science offers early guidance for developing digital tools that are both evidence-based and empathetic, with potential relevance beyond caregiving contexts.

  • Open Access

    What is helpful and not? Patients’ opinions and beliefs of how to support reduced sedentary behavior during cancer treatment—a thematic analysis

    by Anna Henriksson, Anne Söderlund, Magnus L. Elfström, Petra von Heideken Wågert

    Purpose: Understanding patients’ opinions and beliefs regarding how to support an active life and decrease sedentary behavior (SB) during treatment is necessary to inform effective interventions for reduced SB. Therefore, the purpose was to explore the opinions and beliefs of patients receiving neo- or adjuvant cancer treatment on how to support the decrease in SB and how to replace sedentary time. Methods: A purposive sample of patients receiving neo- or adjuvant cancer treatment for breast ( n = 10), prostate ( n = 5), or colorectal cancer ( n = 7) partook in five focus group interviews. Transcripts from the interviews were analyzed with a thematic analysis. Results: Three themes were identified in the analysis: participants describe that the decrease of SB and replacing time in sedentary behavior can be supported by Healthcare and employer engagement , Socialization , and lastly by Self-help . For instance, early information and encouragement from healthcare personnel, adaptations at work, support from relatives and peers, as well as finding routines and setting goals were considered important for reducing SB. Focusing on daily activities and joyful activities were examples of ways to replace sedentary time. Conclusions: Interventions for reducing SB may benefit from addressing several aspects from the patient’s life and focusing on replacing SB with daily activities and not only on health-enhancing physical activity. Healthcare staff should provide early information and continuous encouragement for patients about reducing sedentary behavior during oncological treatment. Collaboration with patients to identify and implement practical strategies such as support from family and friends, workplace adaptations, and goal setting may be helpful.

  • Effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer

    by Olav Vikmoen, Emelie Strandberg, Karianne Vassbakk Svindland, Anna Henriksson, Anne‐Sophie Mazzoni, Birgitta Johansson, Janniz Jönsson, Andreas Karakatsanis, Matilda Annebäck, David Kudrén, et al.

    To investigate the effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy in women with breast cancer on muscle strength, body composition, muscle fiber size, satellite cells, and myonuclei. Women with stage I‐III breast cancer were randomly assigned to a strength training group (ST, n = 23) performing supervised heavy‐load strength training twice a week during chemotherapy, or a usual care control group (CON, n = 17). Muscle strength and body composition were measured and biopsies from m. vastus lateralis collected before the first cycle of chemotherapy (T0) and after chemotherapy and training (T1). Muscle strength increased significantly more in ST than in CON in chest‐press (ST: +10 ± 8%, p < .001, CON: −3 ± 5%, p = .023) and leg‐press (ST: +11 ± 8%, p < .001, CON: +3 ± 6%, p = .137). Both groups reduced fat‐free mass (ST: −4.9 ± 4.0%, p < .001, CON: −5.2 ± 4.9%, p = .004), and increased fat mass (ST: +15.3 ± 16.5%, p < .001, CON: +16.3 ± 19.8%, p = .015) with no significant differences between groups. No significant changes from T0 to T1 and no significant differences between groups were observed in muscle fiber size. For myonuclei per fiber a non‐statistically significant increase in CON and a non‐statistically significant decrease in ST in type I fibers tended ( p = .053) to be different between groups. Satellite cells tended to decrease in ST (type I: −14 ± 36%, p = .097, type II: −9 ± 55%, p = .084), with no changes in CON and no differences between groups. Strength training during chemotherapy improved muscle strength but did not significantly affect body composition, muscle fiber size, numbers of satellite cells, and myonuclei compared to usual care.


  • Open Access

    Exploring sedentary behavior during neo- or adjuvant treatment in patients with cancer: A phenomenological study

    by Anna Henriksson, Magnus L. Elfström, Anne Söderlund, Petra von Heideken Wågert


  • Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer

    by Tim Schauer, Anna Henriksson, Emelie Strandberg, Henrik Lindman, Sveinung Berntsen, Ingrid Demmelmaier, Truls Raastad, Karin Nordin, Jesper F. Christensen

    Background Chemotherapy efficacy is largely dependent on treatment adherence, defined by the relative dose intensity (RDI). Identification of new modifiable risk factors associated with low RDI might improve chemotherapy delivery. Here, we evaluated the association between low RDI and pre-chemotherapy factors, including patient- and treatment-related characteristics and markers of inflammation. Methods This exploratory analysis assessed data from 267 patients with early-stage breast cancer scheduled to undergo (neo-)adjuvant chemotherapy included in the Physical training and Cancer (Phys-Can) trial. The association between low RDI, defined as < 85%, patient-related (age, body mass index, co-morbid condition, body surface area) and treatment-related factors (cancer stage, receptor status, chemotherapy duration, chemotherapy dose, granulocyte colony-stimulating factor) was investigated. Analyses further included the association between RDI and pre-chemotherapy levels of interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP) and Tumor Necrosis Factor-alpha (TNF-α) in 172 patients with available blood samples. Results An RDI of < 85% occurred in 31 patients (12%). Univariable analysis revealed a significant association with a chemotherapy duration above 20 weeks (p < 0.001), chemotherapy dose (p = 0.006), pre-chemotherapy IL-8 (OR 1.61; 95% CI (1.01; 2.58); p = 0.040) and TNF-α (OR 2.2 (1.17; 4.53); p = 0.019). In multivariable analyses, inflammatory cytokines were significant association with low RDI for IL-8 (OR: 1.65 [0.99; 2.69]; p = 0.044) and TNF-α (OR 2.95 [1.41; 7.19]; p = 0.007). Conclusions This exploratory analysis highlights the association of pre-chemotherapy IL-8 and TNF-α with low RDI of chemotherapy for breast cancer. IL-8 and TNF-α may therefore potentially help to identify patients at risk for experiencing dose reductions. Clinical trial number NCT02473003 (registration: June 16, 2015).